Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

—  Company Raises 2023 Revenue and GAAP Net Income Expectations by Approximately $425 Million — —  Conference Call Scheduled for Today at 8:00 a.m. ET — DUBLIN, June 6, 2023 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the … Read more

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

—  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes’ Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the … Read more

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board’s Independent Directors Have Been Appointed Over the Last Four Years, Including Four Directors Designated or Supported by Shareholders Company Launches, Providing Additional Information for Shareholders Alkermes’ Board Recommends Shareholders Vote “FOR” Alkermes’ Director Nominees on Company’s … Read more